Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Propanc Biopharma (Nasdaq: PPCB) announced preclinical results for its lead proenzyme therapy PRP, reporting >85% tumor growth inhibition in pancreatic cancer models and plans for Phase 1b First‑In‑Human trials in 2026.

Rhea-AI Summary

Propanc Biopharma (Nasdaq: PPCB) announced preclinical results for its lead proenzyme therapy PRP, reporting >85% tumor growth inhibition in pancreatic cancer models and plans for Phase 1b First‑In‑Human trials in 2026. The company cited PRP's chemo‑sensitizing effects, reduced fibrosis, stem‑cell targeting, and a $100M facility to support development.

Propanc positions PRP as a potential therapy for advanced solid tumors with initial focus on pancreatic and ovarian cancers; human efficacy and regulatory outcomes remain pending.

Positive

• >85% tumor growth inhibition in preclinical pancreatic models
• Phase 1b First‑In‑Human trials scheduled for 2026
• $100M facility reportedly in place to support development
• Chemo sensitization and reduced fibrosis observed preclinically

Negative

• No human efficacy data yet; results are preclinical
• Clinical and regulatory outcomes are pending and uncertain

Argus Mar 12 session

-13.57% close to close Open Argus

Details

News Market Reaction – PPCB

On Mar 12, the day this news came out, PPCB closed 13.57% below the previous close.

Data tracked by StockTitan Argus for the Mar 12 session.

Market Context

On Mar 12, the day this news came out, the stock closed 13.6% below the previous close. A negative r...

Analysis

On Mar 12, the day this news came out, the stock closed 13.6% below the previous close. A negative reaction despite positive‑sounding PRP data would fit recent patterns where upbeat clinical and corporate updates around PRP coincided with price declines. The backdrop includes significant registered resale capacity and past disclosures of substantial doubt about going‑concern status, which can overshadow preclinical advances. With shares already 99.42% below the 52‑week high, financing and dilution concerns could continue to weigh on sentiment after good news.

Key Figures

Tumor growth inhibition: >85% Pancreatic cancer market size: $3 billion+ Five-year survival rate: 13% +2 more

Tumor growth inhibition

>85%

Preclinical pancreatic cancer models for PRP

Pancreatic cancer market size

$3 billion+

Target treatment market cited in article

Five-year survival rate

13%

Pancreatic cancer five-year survival noted as grim baseline

Phase 1b timing

2026

First‑in‑human Phase 1b trial start targeted

Funding facility

$100M

Facility referenced to support PRP development

Historical Context

5 past events · Latest: Mar 10

5 events

1. Mar 10

   Clinical assay prep

   24h Move

   -20.5%

   FyoniBio agreement to develop LC‑MS PK assay for Phase 1b study.

2. Mar 03

   Preclinical efficacy

   24h Move

   -5.2%

   Highlighted >85% tumor inhibition and plans for 2026 first‑in‑human trial.

3. Feb 18

   Corporate update

   24h Move

   -4.5%

   Half‑year results, IP expansion, and up to $100M private placement facility.

4. Feb 05

   PRP unveiling

   24h Move

   +5.7%

   Positioned PRP as game‑changing therapy for multi‑billion pancreatic market.

5. Jan 27

   IP expansion

   24h Move

   +6.5%

   Filed fourth provisional patent to strengthen PRP formulation protection.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

proenzyme therapy, tumor microenvironment, cancer stem cells, Phase 1b, +2 more

6 terms

proenzyme therapy medical

"PRP, its lead proenzyme therapy poised to potentially disrupt the $3 billion+ pancreatic"

Proenzyme therapy uses inactive enzyme precursors (called proenzymes or zymogens) given to a patient so they become active only after encountering specific conditions in the body. For investors, it matters because this approach aims to deliver targeted biological activity with fewer side effects than always-active drugs, which affects clinical trial design, safety profiles, regulatory hurdles and the potential market value if it proves effective.

tumor microenvironment medical

"Reduces fibrosis and resistance markers in the tumor microenvironment - Sensitizes"

The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

cancer stem cells medical

"- Targets cancer stem cells to cut recurrence risk “PRP may represent a true"

Cells within a tumor that behave like seeds: they can regenerate the cancer, survive treatments, and drive relapse and spread. For investors, therapies that effectively target these cells are important because they promise longer-lasting cures and lower recurrence rates, which can increase the commercial value of a drug or change the outlook for companies developing cancer treatments.

Phase 1b regulatory

"With Phase 1b First-In-Human trials set for 2026 and a $100M facility in place"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

first-in-human regulatory

"With Phase 1b First-In-Human trials set for 2026 and a $100M facility in place"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

chemo sensitization medical

"Root-Cause Attack. Chemo Sensitization. Safer Profile.MELBOURNE, Australia, March 12,"

Chemo sensitization is using a drug or treatment to make cancer cells more vulnerable to chemotherapy so the chemotherapy works better or at lower doses. For investors it matters because successful sensitizers can increase the effectiveness and market value of existing cancer drugs, improve clinical trial results, shorten treatment times, and reduce side effects—think of it as loosening a stubborn lock so the standard key (chemotherapy) can open it more easily.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Root-Cause Attack. Chemo Sensitization. Safer Profile.

MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced highlights of PRP, its lead proenzyme therapy poised to potentially disrupt the $3 billion+ pancreatic cancer treatment market—one of oncology’s most desperate battlegrounds with a grim 13% five-year survival rate.

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game:
- >85% tumor growth inhibition demonstrated in preclinical pancreatic models  
- Forces malignant cells to differentiate—attacking cancer at its root  
- Reduces fibrosis and resistance markers in the tumor microenvironment  
- Sensitizes resistant tumors to standard chemo—higher efficacy, lower toxicity  
- Targets cancer stem cells to cut recurrence risk

“PRP may represent a true paradigm shift for pancreatic cancer patients,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “We’re striking at the disease’s core mechanisms. With Phase 1b First-In-Human trials set for 2026 and a $100M facility in place, we’re moving fast to deliver real hope.”

Propanc is advancing PRP toward clinical development for advanced solid tumors, with pancreatic and ovarian cancers as initial priorities.

Learn more: www.propanc.com

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preclinical result did Propanc (PPCB) report for PRP on March 12, 2026?

Propanc reported >85% tumor growth inhibition in preclinical pancreatic cancer models. According to the company, PRP also reduced fibrosis and resistance markers in the tumor microenvironment.

When will Propanc (PPCB) begin human trials for PRP?

Propanc plans a Phase 1b First‑In‑Human trial in 2026. According to the company, the trial is intended to evaluate safety and initial signals of efficacy in advanced solid tumors.

How might PRP affect chemotherapy for pancreatic cancer (PPCB)?

PRP is reported to sensitize resistant tumors to standard chemotherapy, improving efficacy with lower toxicity. According to the company, preclinical data show enhanced chemo response and reduced resistance markers.

What infrastructure has Propanc (PPCB) announced to support PRP development?

Propanc stated it has a $100M facility in place to support development and trials. According to the company, this facility is intended to accelerate manufacturing and clinical work for PRP.

Is PRP clinically proven to benefit pancreatic cancer patients now?

No; PRP has preclinical evidence only and lacks published human trial outcomes. According to the company, human efficacy will be assessed in the planned Phase 1b trials in 2026.

What cancers is Propanc (PPCB) prioritizing for PRP clinical development?

Propanc prioritizes pancreatic and ovarian cancers as initial targets for PRP development. According to the company, PRP is being advanced toward trials for advanced solid tumors broadly.